Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mafenide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 18/20 | 0.87 |
| ▸ | CA1 | P00915 | 11/20 | 0.87 |
| ▸ | CA12 | O43570 | 8/20 | 0.87 |
| ▸ | CA9 | Q16790 | 8/20 | 0.87 |
| ▸ | CA4 | P22748 | 4/20 | 0.87 |
| ▸ | CA6 | P23280 | 4/20 | 0.87 |
| ▸ | CA5A | P35218 | 4/20 | 0.87 |
| ▸ | CA7 | P43166 | 4/20 | 0.87 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.87 |
| ▸ | CA5B | Q9Y2D0 | 4/20 | 0.87 |
| ▸ | MAPT | P10636 | 1/20 | 0.83 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.75 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.75 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mafenide SCHEMBL41628 | 0.93 | CA2 (1.00) | CA2CA1CA12CA9CA4 | |
| Mafenide SCHEMBL9295695 | 0.93 | CA2 (1.00) | CA2CA1CA12CA9CA4 | |
| Mafenide SCHEMBL1203324 | 0.91 | CA2 (1.00) | CA2CA1CA12CA9CA4 | |
| Mafenide SCHEMBL425524 | 0.91 | CA2 (1.00) | CA2CA1CA12CA9CA4 | |
| Mafenide SCHEMBL2934434 | 0.89 | CA2 (0.91) | CA2CA1CA12CA9CA4 | |
| Mafenide SCHEMBL686407 | 0.89 | CA2 (0.95) | CA2CA1CA12CA9CA4 | |
| Mafenide SCHEMBL27599824 | 0.88 | KDM4E (0.82) | CA2CA1CA12CA9CA4 | |
| Mafenide SCHEMBL27294054 | 0.87 | CA2 (0.87) | CA2CA1CA12CA9CA4 | |
| Mafenide SCHEMBL41627 | 0.86 | SMN1; SMN2 (1.00) | CA2CA1CA12CA9CA4 | |
| Mafenide SCHEMBL26127074 | 0.86 | SMN1; SMN2 (1.00) | CA2CA1CA12CA9CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024133541-A1 | ISOLATED TARGETED DELIVERY SYSTEM FOR THE TREATMENT OF OVARIAN CANCER | CELLIS SP. Z O.O. [LTD.] (PL) | 2024-06-27 | — | — | WO | claimed |
| EP-3310904-B1 | CELLULAR TARGETED ACTIVE INGREDIENT DELIVERY SYSTEM | CELLIS AG (CH) | 2024-04-03 | — | — | EP | claimed |
| WO-2024056413-A1 | ISOLATED TARGETED DELIVERY SYSTEM FOR THE TREATMENT OF GLIOMA | CELLIS AG (CH) | 2024-03-21 | — | — | WO | claimed |
| US-20240060045-A1 | CELLULAR TARGETED ACTIVE INGREDIENT DELIVERY SYSTEM | CELLIS AG (CH) | 2024-02-22 | — | — | US | claimed |
| US-20200030374-A1 | CELLULAR TARGETED ACTIVE INGREDIENT DELIVERY SYSTEM | CELLIS AG (CH) | 2020-01-30 | — | — | US | claimed |
| US-20190328911-A1 | CELLULAR TARGETED PHARMACEUTICALLY ACTIVE SUBSTANCE OR LABEL DELIVERY SYSTEM | CELLIS AG (CH) | 2019-10-31 | — | — | US | claimed |
| US-10383950-B2 | Methods and compositions of carrier systems for the purpose of intracellular drug targeting | HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH (DE/DE) (DE) | 2019-08-20 | — | — | US | claimed |
| WO-2019154859-A1 | FAP INHIBITOR | Universität Heidelberg (DE) | 2019-08-15 | — | — | WO | claimed |
| EP-3475415-A1 | CELLULAR TARGETED PHARMACEUTICALLY ACTIVE SUBSTANCE OR LABEL DELIVERY SYSTEM | Cellis AG (CH) | 2019-05-01 | — | — | EP | claimed |
| EP-3310904-A1 | CELLULAR TARGETED ACTIVE INGREDIENT DELIVERY SYSTEM | Cellis Sp. z.o.o. (Ltd.) (PL) | 2018-04-25 | — | — | EP | claimed |
| EP-1717247-A1 | Cyclic peptides binding to the somatostatin receptor | Schering AG (DE) | 2006-11-02 | — | — | EP | claimed |
| EP-1706420-A1 | SITE-SPECIFIC COUPLING OF POLYPEPTIDES | Pharmexa A/S (DK) | 2006-10-04 | — | — | EP | claimed |
| EP-1689365-A1 | DRUG DELIVERY VEHICLES AND USES THEREOF | Pharmexa A/S (DK) | 2006-08-16 | — | — | EP | claimed |
| EP-1689778-A1 | RGD TARGETING MOIETY ITS PORDUCTION AND USE | Pharmexa A/S (DK) | 2006-08-16 | — | — | EP | claimed |
| WO-2005070960-A1 | SITE-SPECIFIC COUPLING OF POLYPEPTIDES | PHARMEXA A/S (DK) | 2005-08-04 | — | — | WO | claimed |
| EP-1557429-A1 | Site-directed coupling of proteins | Vectron Therapeutics AG (DE) | 2005-07-27 | — | — | EP | claimed |
| WO-2005053642-A1 | DRUG DELIVERY VEHICLES AND USES THEREOF | PHARMEXA A/S (DK) | 2005-06-16 | — | — | WO | claimed |
| WO-2005054293-A1 | RGD TARGETING MOIETY ITS PORDUCTION AND USE | PHARMEXA A/S (DK) | 2005-06-16 | — | — | WO | claimed |
| EP-1537858-A1 | Drug delivery vehicles and uses thereof | Vectron Therapeutics AG (DE) | 2005-06-08 | — | — | EP | claimed |
| EP-1538164-A1 | RGD targeting moiety its production and use | Vectron Therapeutics AG (DE) | 2005-06-08 | — | — | EP | claimed |